| scholarly article | Q13442814 |
| P50 | author | Massimo Falconi | Q37378032 |
| Davide Campana | Q45862458 | ||
| Guido Rindi | Q56849391 | ||
| P2093 | author name string | Claudio Pasquali | |
| Alessandro Zerbi | |||
| Gianfranco Delle Fave | |||
| Letizia Boninsegna | |||
| Vanessa Capitanio | |||
| AISP-Network Study Group | |||
| P2860 | cites work | Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients | Q57425794 |
| Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas | Q57425890 | ||
| Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas | Q57767637 | ||
| Clinicopathological Features of Pancreatic Endocrine Tumors: A Prospective Multicenter Study in Italy of 297 Sporadic Cases | Q57820083 | ||
| Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients | Q77348249 | ||
| Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours | Q24241069 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors | Q28290833 | ||
| Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours | Q33783119 | ||
| Sunitinib malate for the treatment of pancreatic neuroendocrine tumors | Q34163515 | ||
| ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors | Q34248466 | ||
| Everolimus for advanced pancreatic neuroendocrine tumors. | Q34399809 | ||
| Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting | Q34743520 | ||
| Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review | Q35371197 | ||
| TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. | Q35837124 | ||
| Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). | Q36741130 | ||
| Surgery on neuroendocrine tumours | Q36768667 | ||
| Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. | Q36793415 | ||
| Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors | Q37175960 | ||
| Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? | Q37277977 | ||
| Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). | Q37688704 | ||
| Gastrointestinal neuroendocrine tumors | Q37799954 | ||
| Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review | Q37847859 | ||
| New treatment strategies in advanced neuroendocrine tumours | Q37943618 | ||
| Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches | Q38003308 | ||
| Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections | Q39681051 | ||
| Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors | Q42744657 | ||
| Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group | Q43286770 | ||
| Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival | Q44494869 | ||
| Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers | Q44676949 | ||
| TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. | Q47867776 | ||
| P433 | issue | 12 | |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| P304 | page(s) | 935-943 | |
| P577 | publication date | 2013-03-08 | |
| P1433 | published in | Hepato Pancreato Biliary | Q15756742 |
| P1476 | title | Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study | |
| P478 | volume | 15 |
| Q41148371 | Clinical presentation in insulinoma predicts histopathological tumour characteristics. |
| Q38537928 | Meta-analysis of Liver Resection Versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases |
| Q39159369 | Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection. |
| Q38752172 | Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study |
| Q59807139 | Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: |
| Q45797561 | Targeted therapies, prognostic and predictive factors in endocrine oncology |
Search more.